The Development, Indications, and the Safety of Monoclonal Antibodies

Monoclonal antibodies (mAbs) are described as brand-new tools used in the therapy of cancer, autoimmune and infectious diseases, transplant rejection, and some other new indications. MAbs have been shown to create some adverse events such as hypersensitivity reactions, immunological problems, cardiovascular diseases, respiratory events, proteinuria, nephrotoxicity, dermatologic events, and cytopenia. In this review, our purpose is to overview the indications and the unwanted events matched with these drugs and negotiate the developments in the development of these drugs that are able to increase the efficacy and decrease the safety problems.

Keywords: Adverse effect; Cancer molecular biology; Clinical drug studies; Drug development; Monoclonal antibody